Biotechnology

French giant Efor deepens its North American footprint, acquiring CQV specialist DynamixE to target the complex cell and gene therapy manufacturing market.

After a major turnaround, Genetix Biotherapeutics announces its first profitable quarter and plans to double production of its high-stakes gene therapies.

Regulatory delays in China scuttled Pulmatrix's merger with Cullgen, forcing the biotech to urgently seek new partners for its promising drug pipeline.

For millions suffering from relentless chronic cough with no approved treatments, Trevi Therapeutics' Haduvio offers a new possibility backed by strong clinical data.

Fresh off a major clinical trial victory, Alumis Inc. heads to a key investor conference. What's next for its promising pipeline and soaring stock?

After a dramatic pivot and massive fundraising, Galecto will detail its new hematology pipeline at a key conference. Here’s what investors are watching.

In a strategic reverse merger with Rallybio, T-cell therapy innovator Candid Therapeutics secures over $505M to advance its groundbreaking autoimmune pipeline.

UroGen's new bladder cancer drug sees rapid uptake post-reimbursement code, but a $153M loss and fresh debt highlight its high-stakes growth strategy.

With major trials underway for its cancer and vision drugs, NovaBridge's upcoming investor presentation could be a pivotal moment for the biotech firm.

Asia's largest pharma show returns, showcasing China's evolution from the world's factory to a global hub of drug innovation and supply chain strategy.

With a strong cash position and promising drug candidate, Apogee Therapeutics is advancing multiple trials to challenge the I&I market with a new therapy.

Lynk Pharmaceuticals reports its oral drug zemprocitinib met all goals in a late-stage study for atopic dermatitis, offering rapid itch relief and a strong safety profile.

As MSA Awareness Month begins, a novel drug from Alterity Therapeutics shows significant promise in slowing the devastating and untreatable neurodegenerative disease.

A key clinical milestone for its MS drug azer-cel nets Precision BioSciences $7.5M, extending its financial runway and boosting hope for patients.

With a strong cash runway and pivotal trials underway, Sionna Therapeutics aims to revolutionize CF treatment with a novel class of NBD1 stabilizer drugs.

Hopes for a new Huntington's gene therapy face a major delay as the FDA rejects uniQure's current data and calls for a more rigorous, complex study.

Zymeworks lands $250M from Royalty Pharma in a non-dilutive deal, validating its cancer drug Ziihera and highlighting a new era of biotech financing.

With positive Phase 3 data for its first-in-class Stargardt disease drug and a massive new financing round, Belite Bio pivots toward commercialization.

A Chinese firm's 'Global Pioneer' status in cellular essence sparks debate on the future of biotech in cosmetics, medicine, and global regulation.

Shareholder approval paves the way for cancer therapy innovator VERAXA to go public, aiming to accelerate its next-gen antibody-drug conjugate pipeline.